Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Dumps Generic Drugs Business, Looks For More Device Targets

This article was originally published in The Gray Sheet

Executive Summary

Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.

You may also be interested in...



As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails

Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.

Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz

Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.

Expert Panel Says Interoperability Remains Barrier In Digital Surgery Transformation

An expert panel foresees increased adoption of digital tools in the OR, not just robotics. These tools help surgeons make more informed decisions and improve outcomes, but barriers remain.

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT033153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel